These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 26424596)
21. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis. Robert G; Jannink S; Smit F; Aalders T; Hessels D; Cremers R; Mulders PF; Schalken JA Prostate; 2013 Jan; 73(2):113-20. PubMed ID: 22674214 [TBL] [Abstract][Full Text] [Related]
22. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Danila DC; Anand A; Sung CC; Heller G; Leversha MA; Cao L; Lilja H; Molina A; Sawyers CL; Fleisher M; Scher HI Eur Urol; 2011 Nov; 60(5):897-904. PubMed ID: 21802835 [TBL] [Abstract][Full Text] [Related]
23. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Esgueva R; Perner S; J LaFargue C; Scheble V; Stephan C; Lein M; Fritzsche FR; Dietel M; Kristiansen G; Rubin MA Mod Pathol; 2010 Apr; 23(4):539-46. PubMed ID: 20118910 [TBL] [Abstract][Full Text] [Related]
24. Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models. Linn DE; Bronson RT; Li Z PLoS One; 2015; 10(3):e0120628. PubMed ID: 25780911 [TBL] [Abstract][Full Text] [Related]
25. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Chaux A; Albadine R; Toubaji A; Hicks J; Meeker A; Platz EA; De Marzo AM; Netto GJ Am J Surg Pathol; 2011 Jul; 35(7):1014-20. PubMed ID: 21677539 [TBL] [Abstract][Full Text] [Related]
26. Molecular characterization and clinical impact of TMPRSS2-ERG rearrangement on prostate cancer: comparison between FISH and RT-PCR. Fernández-Serra A; Rubio L; Calatrava A; Rubio-Briones J; Salgado R; Gil-Benso R; Espinet B; García-Casado Z; López-Guerrero JA Biomed Res Int; 2013; 2013():465179. PubMed ID: 23781502 [TBL] [Abstract][Full Text] [Related]
27. Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer. Hashim D; Gonzalez-Feliciano AG; Ahearn TU; Pettersson A; Barber L; Pernar CH; Ebot EM; Isikbay M; Finn SP; Giovannucci EL; Lis RT; Loda M; Parmigiani G; Lotan T; Kantoff PW; Mucci LA; Graff RE Int J Cancer; 2020 May; 146(10):2694-2702. PubMed ID: 31318977 [TBL] [Abstract][Full Text] [Related]
28. ERG rearrangement is present in a subset of transition zone prostatic tumors. Falzarano SM; Navas M; Simmerman K; Klein EA; Rubin MA; Zhou M; Magi-Galluzzi C Mod Pathol; 2010 Nov; 23(11):1499-506. PubMed ID: 20693982 [TBL] [Abstract][Full Text] [Related]
29. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Leyten GH; Hessels D; Jannink SA; Smit FP; de Jong H; Cornel EB; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; van Oort IM; Mulders PF; Hulsbergen-van de Kaa CA; Schalken JA Eur Urol; 2014 Mar; 65(3):534-42. PubMed ID: 23201468 [TBL] [Abstract][Full Text] [Related]
30. TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer. Jiang H; Mao X; Huang X; Zhao J; Wang L; Xu J; Zhang H; Lu Y; Yu Y Tumour Biol; 2016 Sep; 37(9):12397-12402. PubMed ID: 27320318 [TBL] [Abstract][Full Text] [Related]
31. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Mosquera JM; Mehra R; Regan MM; Perner S; Genega EM; Bueti G; Shah RB; Gaston S; Tomlins SA; Wei JT; Kearney MC; Johnson LA; Tang JM; Chinnaiyan AM; Rubin MA; Sanda MG Clin Cancer Res; 2009 Jul; 15(14):4706-11. PubMed ID: 19584163 [TBL] [Abstract][Full Text] [Related]
32. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy. Rubio-Briones J; Fernández-Serra A; Calatrava A; García-Casado Z; Rubio L; Bonillo MA; Iborra I; Solsona E; López-Guerrero JA J Urol; 2010 May; 183(5):2054-61. PubMed ID: 20303538 [TBL] [Abstract][Full Text] [Related]
33. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Han B; Mehra R; Lonigro RJ; Wang L; Suleman K; Menon A; Palanisamy N; Tomlins SA; Chinnaiyan AM; Shah RB Mod Pathol; 2009 Aug; 22(8):1083-93. PubMed ID: 19407851 [TBL] [Abstract][Full Text] [Related]
34. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054 [TBL] [Abstract][Full Text] [Related]
35. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Furusato B; Gao CL; Ravindranath L; Chen Y; Cullen J; McLeod DG; Dobi A; Srivastava S; Petrovics G; Sesterhenn IA Mod Pathol; 2008 Feb; 21(2):67-75. PubMed ID: 18065961 [TBL] [Abstract][Full Text] [Related]
36. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion. Burdelski C; Menan D; Tsourlakis MC; Kluth M; Hube-Magg C; Melling N; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Simon R; Schlomm T; Steurer S; Krech T BMC Cancer; 2015 Jul; 15():538. PubMed ID: 26202067 [TBL] [Abstract][Full Text] [Related]
37. Clinical impact of ERG and PTEN status in prostate cancer patients underwent radical prostatectomy. Fragkoulis C; Glykas I; Tzelves L; Stamatakos PV; Papadopoulos G; Stathouros G; Dellis A; Ntoumas K; Kostopoulou A; Deliveliotis C; Papatsoris A Arch Ital Urol Androl; 2022 Dec; 94(4):390-395. PubMed ID: 36576468 [TBL] [Abstract][Full Text] [Related]
38. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer. Bismar TA; Yoshimoto M; Vollmer RT; Duan Q; Firszt M; Corcos J; Squire JA BJU Int; 2011 Feb; 107(3):477-85. PubMed ID: 20590547 [TBL] [Abstract][Full Text] [Related]
39. Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer. Kulda V; Topolcan O; Kucera R; Kripnerova M; Srbecka K; Hora M; Hes O; Klecka J; Babuska V; Rousarova M; Benson V; Pesta M Anticancer Res; 2016 Sep; 36(9):4787-93. PubMed ID: 27630329 [TBL] [Abstract][Full Text] [Related]
40. Identification of TMPRSS2-ERG mechanisms in prostate cancer invasiveness: Involvement of MMP-9 and plexin B1. Liu B; Gu X; Huang T; Luan Y; Ding X Oncol Rep; 2017 Jan; 37(1):201-208. PubMed ID: 28004109 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]